UPDATE: ProstACT Global Phase 3 Trial for TLX591 Dosed The First Patient

/in , , /by

ProstACT Global is a pivotal randomized Phase 3 study testing the PSMA-targeted radiopharmaceutical TLX591 (lutetium‑177 rosopatamab tetraxetan) in metastatic castration‑resistant prostate cancer. The trial has just moved into its randomized expansion phase, with the first patient in this part dosed at a specialized prostate cancer center in Melbourne, marking a key transition from safety/dosimetry work […]

Read more

UPDATE: TD001 a New Potent ADC for Prostate Cancer Expressing PSMA Enters Phase 1/2

/in , , , /by

TD001, is an investigational antibody-drug conjugate directed against prostate-specific membrane antigen (PSMA), developed for the treatment of men with metastatic castration-resistant prostate cancer whose tumors express PSMA will start recruiting patients for its phase 1/2 clinical trial. Mechanistically, TD001 combines a monoclonal antibody directed against PSMA with a topoisomerase I inhibitor payload, exatecan, linked through […]

Read more

PROSTest: Blood mRNA Assay Predicts 177Lu-PSMA Success in mCRPC After One Cycle

/in /by

A study presented at the 2025 Society of Urologic Oncology (SUO) Annual Meeting has introduced PROSTest, a novel blood-based mRNA assay that accurately predicts treatment outcomes for 177Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer (mCRPC) patients. The multi-center investigation analyzed 268 PET-positive mCRPC patients from centers in Munster, Basel, and Essen, all with median […]

Read more

REVELUTION Trial: GnRH Antagonists Show Less Coronary Plaque Progression Than Agonists in Prostate Cancer ADT

/in , , /by

Relugolix showed less coronary plaque progression than leuprolide in men receiving androgen deprivation therapy with prostate cancer and pelvic radiotherapy, according to the REVELUTION trial. The prospective study enrolled 94 ADT-naïve men from June 2022 to March 2024, with 90 completing analysis across three arms: radiotherapy alone (n=28), radiotherapy plus leuprolide (n=31), and radiotherapy plus […]

Read more

Triaptosis: a New Way to Kill Cancer Using Menadione

/in /by

A new form of cell death called triaptosis is starting to attract attention as a potential way to treat hard‑to‑kill cancers. The idea behind it is quite simple: instead of trying to push tumor cells into the classic death routes that many of them have already learned to escape, triaptosis hits them somewhere they are […]

Read more

AI Developed ISM3830 a New CBLB Inhibitor

/in /by

Insilico Medicine has nominated ISM3830, a potentially best-in-class oral CBLB inhibitor discovered through its proprietary Chemistry42 AI platform, as a preclinical candidate for advanced cancer immunotherapy. This novel molecule targets Casitas B-lineage lymphoma-b (CBLB), an intracellular E3 ubiquitin ligase that acts as a master negative regulator of T-cell and natural killer (NK) cell activation, distinct […]

Read more

Phase 1 Trial for ITC-6146RO, Antibody-Drug Conjugate Targeting B7-H3

/in , , /by

ITC-6146RO is an experimental cancer drug belonging to the class of antibody–drug conjugates, or ADCs. It received IND Approval from Korean Ministry of Food and Drug Safety (Following U.S. FDA) to start a first‑in‑human Phase 1 trial in people with advanced or metastatic solid tumors who no longer respond to standard therapies. It has been […]

Read more

Phase 1/2 Trial for MK-6070 (Gocatamig): A Promising Trispecific T-Cell Engager for Neuroendocrine Cancers

/in , , /by

MK-6070 (Gocatamig) is an engineered trispecific T-cell engager designed to target a protein called DLL3, which is predominantly found on certain aggressive neuroendocrine tumors, including prostate cancer. This molecule works by simultaneously binding to DLL3 on tumor cells, the CD3 receptor on T cells, and serum albumin, which extends the drug’s circulation time in the […]

Read more